Revenue Breakdown
Composition ()
No data
Revenue Streams
Avalo Therapeutics Inc (AVTX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Prescription drugs, accounting for 66.9% of total sales, equivalent to $3.62M. Another important revenue stream is Prescribed dietary supplements. Understanding this composition is critical for investors evaluating how AVTX navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Avalo Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -177.05%, provide a clear picture of how effectively AVTX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, AVTX competes directly with industry leaders such as DERM and RLMD. With a market capitalization of $279.54M, it holds a significant position in the sector. When comparing efficiency, AVTX's gross margin of N/A stands against DERM's 61.32% and RLMD's N/A. Such benchmarking helps identify whether Avalo Therapeutics Inc is trading at a premium or discount relative to its financial performance.
